Hung-Jen Chen

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Topics

Chronic Myeloid Leukemia

Epidermal Growth Factor Receptor

Ejection Fraction

Top Venues

Thoracic cancer

Diagnostics (Basel, Switzerland)

OncoTargets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. Cancers 15 (3) (2023)
Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. Cancers 15 (3) (2023)
Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Hung-Jen Chen, Te-Chun Hsia, Chia-Hung Chen, Chih-Yen Tu
The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer. Diagnostics (Basel, Switzerland) 13 (1) (2022)
Wen-Chien Cheng, Yi-Cheng Shen, Chun-Ru Chien, Wei-Chih Liao, Chia-Hung Chen, Te-Chun Hsia, Chih-Yeh Tu, Hung-Jen Chen
The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan. Thoracic cancer 13 (10) (2022)
Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Hung-Jen Chen, Te-Chun Hsia, Chia-Hung Chen, Chih-Yen Tu
The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer. Diagnostics (Basel, Switzerland) 13 (1) (2022)
Chia-Ling Li, Te-Chun Hsia, Su-Tso Yang, Kun-San Clifford Chao, Chih-Yen Tu, Hung-Jen Chen, Chia-Hsiang Li
Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. Integrative cancer therapies 21 (2022)
Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Hung-Jen Chen, Te-Chun Hsia, Chia-Hung Chen, Chih-Yen Tu
The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer. Diagnostics (Basel, Switzerland) 13 (1) (2022)
Kuo-Yang Huang, Hung-Jen Chen, Ching-Hsiung Lin, Bing-Yen Wang, Ching-Yuan Cheng, Sheng-Hao Lin
Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis. Thoracic cancer 13 (13) (2022)
Wen-Chien Cheng, Te-Chun Hsia, Chih-Yen Tu, Hung-Jen Chen
The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. OncoTargets and therapy 13 (2021)
Hung-Jen Chen, Chih-Yen Tu, Kuo-Yang Huang, Chun-Ru Chien, Te-Chun Hsia
Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma. PloS one 15 (12) (2020)
How-Yang Tseng, Yi-Cheng Shen, Yen-Sung Lin, Chih-Yen Tu, Hung-Jen Chen
Etiologies of delayed diagnosis and six-month outcome of patients with newly diagnosed advanced lung cancer with respiratory failure at initial presentation. Thoracic cancer 11 (9) (2020)